# Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.

> **NCT03643575** · PHASE1 · COMPLETED · sponsor: **Reckitt Benckiser Inc.** · enrollment: 30 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Vicks Cough Syrup for Chesty Coughs
- **DRUG:** Robitussin Extra Strength Chest Congestion
- **DRUG:** Organ-I- NR tablet

## Key facts

- **NCT ID:** NCT03643575
- **Lead sponsor:** Reckitt Benckiser Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-30
- **Primary completion:** 2009-07-16
- **Final completion:** 2009-07-16
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03643575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03643575, "Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03643575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*